Commercial Operations

BMS to Create Oncology Drug Powerhouse with Celgene Acquisition

Similarly, Celgene’s blood cancer drug Imnovid/Pomalyst (pomalidomide) saw sales of $513 million in the third quarter, a 23 percent year-over-year increase, and its non-small cell lung cancer treatment Abraxane (paclitaxel) saw revenues increase by 15 percent year-over-year to $288 million. Read More